Welcome to our dedicated page for Select Medical SEC filings (Ticker: SEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Select Medical Holdings Corporation SEC filings document the formal disclosures of a NYSE-listed healthcare services company with common stock traded under SEM. Its Form 8-K reports cover operating results and financial condition, material-event disclosures, capital-structure information, employment and compensation-related agreements, and Regulation FD communications.
Proxy materials and annual-meeting filings describe director elections, executive compensation votes, auditor ratification, board-structure proposals, stockholder meeting rights and voting outcomes. The filings also record governance matters and corporate reporting related to Select Medical's hospital and outpatient rehabilitation operations.
Select Medical Holdings Corp. (NYSE: SEM) filed an 8-K to disclose board-approved amendments that completely restate the company’s bylaws, effective July 30 2025.
Key change: the revised bylaws tighten the advance-notice process for stockholder director nominations and other business in response to the SEC’s universal proxy rules (Rule 14a-19). A nominating stockholder must now:
- State its intent to deliver a proxy statement and form of proxy to holders representing ≥67% of the voting power entitled to vote on director elections, and include all information required by Rule 14a-19.
- Provide evidence that it has actually solicited proxies from holders of at least 67% of outstanding voting power.
The amended bylaws also make assorted clarifying and procedural updates to the company’s existing advance-notice provisions. The full text is filed as Exhibit 3.1.
No financial results, transactions, or earnings data are included in this report.
Insider activity: Director Thomas Daniel filed Form 4 for Select Medical Holdings (SEM) disclosing a grant of 14,035 restricted shares on 07/29/2025 (transaction code “A”). The award carries a $0 purchase price and vests in full on 07/29/2026. Following the grant, Daniel directly owns 80,035 common shares; no derivative securities or sales were reported.
The filing represents routine director compensation and modestly increases insider ownership. No cash outlay, option exercises or open-market purchases occurred, so the transaction is unlikely to materially affect near-term supply-demand dynamics for SEM shares.